An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder

This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/d over 52 weeks in patients who completed the 6-week double-blind study CLIC477D2302.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bipolar I Disorder

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

written informed consent provided prior to participation in the extension study.
successful completion of the study CLIC477D2302
willingness and ability to comply with all study requirements

Exclusion criteria

premature discontinuation from the study CLIC477D2302
failure to comply with the study CLIC477D2302 protocol

Treatment and study plan

Licarbazepine

Drug

Primary outcomes

Safety and tolerability of licarbazepine with respect to adverse events, serious adverse events, changes in laboratory values, ECGs and vital signs.

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder.

Important dates

Study start: 2005
Primary completion: 2007
Study completion: 2007
First posted: Oct 13, 2005
Registry last updated: Mar 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed